Synlogic (SYBX) AI Stock Analysis

• Market Cap: $13.80M
• Dividend Yield: N/A
• Average Volume (3M): 8.28K
• Price to Earnings (P/E): 10.2
• Beta (1Y): 0.49
• Revenue Growth: -99.76%
• EPS Growth: 76.96%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): 0.03
• Shares Outstanding: 11,696,109
• 10 Day Avg. Volume: 6,429
• 30 Day Avg. Volume: 8,282
• PEG Ratio: 0.06
• Price to Book (P/B): 0.66
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.95
• Enterprise Value/Market Cap: 4.27
• Enterprise Value/Revenue: 9.89
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.48
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

The overall stock score for Synlogic is low, driven primarily by ongoing financial challenges, including persistent losses and negative cash flows. The downward technical indicators further reflect market skepticism. Additionally, the negative valuation metrics underscore the company's struggle with profitability. The lack of positive earnings or dividends makes the stock less appealing to investors, contributing to the overall bearish outlook.

Synlogic Business Overview & Revenue Model

Company Description

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Synlogic makes money primarily through the development and potential commercialization of its Synthetic Biotic medicines. The company is engaged in partnerships and collaborations with other biotechnology and pharmaceutical firms to advance its research and development efforts, which can provide milestone payments and research funding. Additionally, Synlogic aims to generate revenue through licensing agreements and eventual sales of its therapeutic products upon successful clinical trials and regulatory approvals.

Synlogic Financial Statement Overview

Summary

Synlogic presents a mixed financial picture. While revenue growth is promising, profitability remains a challenge with persistent losses. The company benefits from a strong equity base without debt, providing some financial cushion. However, negative cash flows emphasize the need for careful cash management and operational improvements to achieve long-term viability.

Income Statement

The income statement reveals a low revenue base with high growth (137.4% from 2023 to 2024) but persistent negative margins. The net profit margin remains negative at -291.99%, indicating ongoing unprofitability. The company is facing significant operational losses reflected in negative EBIT and EBITDA margins, pointing to inefficiencies and high fixed costs.

Balance Sheet

The balance sheet shows a strong equity position with no debt, providing financial stability. Synlogic maintains a 64.31% equity ratio, indicating reliance on equity financing. However, the decreasing total assets over years may pose a risk if trends continue. The company maintains a healthy cash balance, critical for operations and strategic initiatives.

Cash Flow

The cash flow statement highlights significant negative free cash flow, although improved from the previous year (-38.89%). The operating cash flow to net income ratio is negative, reflecting cash consumption in operations. The firm benefits from financing activities and investments, partially offsetting operational cash deficits. Strategic cash management remains crucial.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	8.00K	3.37M	1.18M	1.75M	545.00K
Gross Profit	0.00	8.00K	3.37M	-4.49M	1.75M	545.00K
EBITDA	288.00K	-22.06M	-53.20M	-63.63M	-58.12M	-57.83M
Net Income	1.50M	-23.36M	-57.28M	-64.88M	-58.12M	-56.54M
Balance Sheet
Total Assets	17.97M	19.83M	75.55M	110.86M	174.74M	143.84M
Cash, Cash Equivalents and Short-Term Investments	17.27M	18.86M	47.75M	77.63M	136.63M	100.44M
Total Debt	0.00	0.00	17.27M	20.30M	20.59M	22.81M
Total Liabilities	4.87M	7.08M	32.90M	28.25M	27.47M	28.70M
Stockholders Equity	13.09M	12.75M	42.66M	82.61M	147.27M	115.14M
Cash Flow
Free Cash Flow	-17.44M	-31.67M	-51.83M	-57.62M	-52.88M	-39.95M
Operating Cash Flow	-17.82M	-31.66M	-51.61M	-56.89M	-52.20M	-39.55M
Investing Cash Flow	9.07M	25.34M	38.77M	58.35M	-53.25M	32.48M
Financing Cash Flow	156.00K	172.00K	20.94M	-2.04M	89.38M	13.39M

Synlogic Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.20
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYBX, the sentiment is Negative. The current price of 1.2 is below the 20-day moving average (MA) of 1.22, above the 50-day MA of 1.17, and below the 200-day MA of 1.33, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 49.62 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SYBX.

Synlogic Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.50B	0.32	-61.87%	2.27%	17.10%	1.59%
SYBX	45 Neutral	$13.80M	10.24	11.34%	―	-99.76%	76.96%
MBRX	44 Neutral	$7.82M	―	-214.79%	―	―	52.82%
MRKR	44 Neutral	$17.76M	―	-97.30%	―	-3.23%	38.05%
PHIO	42 Neutral	$11.90M	―	-76.12%	―	―	81.71%
IMNN	41 Neutral	$16.26M	―	-397.54%	―	―	24.16%
INAB	34 Underperform	$7.13M	―	-174.66%	―	―	38.53%